葡萄糖转运蛋白1、人类血管内皮生长因子C、核因子κB在乳腺浸润性导管癌组织中的表达及其对患者预后的影响

doi:10.3760/cma.j.cn101202-20200119-00014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1065 KB) HTML (2 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨葡萄糖转运蛋白1(GLUT-1)、人类血管内皮生长因子C(VEGF-C)、核因子κB(NF-κB)在乳腺浸润性导管癌组织中的表达及其对患者预后的影响。方法回顾性研究。纳入2011年1月—2014年11月蚌埠市第三人民医院117例乳腺浸润性导管癌患者(年龄20~79岁)的临床资料及癌组织病理学标本,并随机采集其中51例患者的癌旁组织标本。以免疫组织化学法检测标本中GLUT-1、VEGF-C、NF-κB的表达,比较其在癌组织和癌旁组织中表达量的差异,分析阳性表达与浸润性导管癌临床病理因素的关系,及其对临床预后的影响。结果 GLUT-1、NF-κB、VEGF-C在浸润性导管癌组织中阳性表达率高于癌旁组织,差异均有统计学意义(χ²=45.785、48.433、48.236, P值均<0.01)。GLUT-1、NF-κB、VEGF-C在不同肿瘤大小、有无淋巴浸润、不同TNM分期和病理分级患者阳性表达率的差异均有统计学意义(P值均<0.05)。117例浸润性导管癌患者中,失访7例,死亡32例。110例随访的乳腺浸润性导管癌患者中,GLUT-1阳性表达患者的5年生存率(21.82%)显著低于阴性表达患者(77.09%),差异有统计学意义(χ²=10.854,P<0.01);NF-κB、VEGF-C阳性表达与阴性表达患者5年生存率差异均无统计学意义(χ²=0.843、0.852,P值均>0.05)。结论 GLUT-1、VEGF-C、NF-κB表达升高可能参与了乳腺浸润性导管癌的侵袭进展过程,其中GLUT-1是影响患者预后的高风险因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	葛杰
	王颖
	沈铁骁
	王名海
	王荣寅

关键词 ：癌,导管,乳腺, 乳腺浸润性导管癌, 葡萄糖转运蛋白-1, 人类血管内皮生长因子C, 核因子κB , 免疫组织化学, 预后

Abstract：Objective To observe the expression and clinical significance of glucose transporter 1(GLUT-1), vascular endothelial growth factor C(VEGF-C), nuclear faetor-κB(NF-κB)in invasive ductal carcinoma of the breast.Methods The expression of GLUT-1, VEGF-C, and NF-κB in 117 cases of invasive ductal carcinoma and 51 cases of pericarcinous tissues collected from January 2011 to November 2014 was detected by immunohistochemistry. The patients were aged 20-79 years. The relationship between the expression of GLUT-1, VEGF-C, and NF-κB and the clinicopathological characteristics and survival times of the patients was then analyzed.Results Differences in GLUT-1, NF-κB, and VEGF-C expression in normal tissues, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and breast tissue with lymph node metastasis were statistically significant (χ²=45.785, 48.433, 48.236, all P values<0.01). The positive expression rates of GLUT-1, NF-κB, and VEGF-C were correlated with tumor size, lymphatic infiltration, TNM stage, and pathological grade (all P values<0.05). Of the 117 patients with invasive ductal carcinoma, 7 were lost to follow up and 32 passed away. Among 110 patients with infiltrating ductal carcinoma of the breast, the 5-year survival rate of patients with positive GLUT-1 expression (21.82%) was notably lower than that of patients with negative expression (77.09%); the difference observed was statistically significant (χ²=10.854,P<0.01). No significant difference in 5-year survival rate between patients with positive and negative NF-κB and VEGF-C expression was observed (χ²=0.843, 0.852, all P values>0.05).Conclusions Increased expression of GLUT-1, VEGF-C, and NF-κB may be involved in the invasion and progression of infiltrating ductal carcinoma of the breast. Moreover, GLUT-1 is a high-risk factor affecting the prognosis of patients.

Key words： Carcinoma, ductal, breast Invasive ductal carcinoma of the breast Glucose transporter1 Vascular endothelial growth factor C Nuclear faetor-κB Immunohistochemistry Prognosis

收稿日期: 2020-01-19

基金资助:国家自然科学基金(81903619)

通讯作者: 王荣寅,Email:wangying_0711@126.com

引用本文:

葛杰, 王颖, 沈铁骁, 王名海, 王荣寅. 葡萄糖转运蛋白1、人类血管内皮生长因子C、核因子κB在乳腺浸润性导管癌组织中的表达及其对患者预后的影响[J]. 中华解剖与临床杂志, 2020, 25(5): 537-541.
Ge Jie, Wang Ying, Shen Tiexiao, Wang Minghai, Wang Rongyin. Expression and clinical significance of glucose transporter 1, vascular endothelial growth factor C, and nuclear faetor-κB in invasive ductal carcinoma of the breast. Chinese Journal of Anatomy and Clinics, 2020, 25(5): 537-541.

链接本文:

http://www.cjac.com.cn/CN/10.3760/cma.j.cn101202-20200119-00014 或 http://www.cjac.com.cn/CN/Y2020/V25/I5/537

[1]	Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. Breast cancer in the 21st century: from early detection to new therapies[J]. Radiologia, 2017, 59(5): 368-379. DOI:10.1016/j.rx.2017.06.003.
[2]	Schwartz L, Supuran CT, Alfarouk KO. The warburg effect and the hallmarks of cancer[J]. Anticancer Agents Med Chem, 2017, 17(2): 164-170. DOI:10.2174/1871520616666161031143301.
[3]	Pan Y, Zheng Q, Ni W, et al. Breaking glucose transporter 1/pyruvate kinase M2 glycolytic loop is required for cantharidin inhibition of metastasis in highly metastatic breast cancer[J]. Front Pharmacol, 2019, 10: 590. DOI:10.3389/fphar.2019.00590.
[4]	Tsutsui S, Inoue H, Yasuda K, et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density[J]. Breast Cancer Res Treat, 2006, 98(3): 261-266. DOI:10.1007/s10549-005-9157-9.
[5]	Zhao H, Sun J, Shao J, et al. Glucose transporter 1 promotes the malignant phenotype of non-small cell lung cancer through integrin β1/Src/FAK signaling[J]. J Cancer, 2019, 10(20): 4989-4997. DOI:10.7150/jca.30772.
[6]	Sun H, Miao C, Liu W, et al. TGF-β1/TβRII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages[J]. Biochem Biophys Res Commun, 2018, 497(2): 583-590. DOI:10.1016/j.bbrc.2018.02.104.
[7]	Long L, Pang XX, Lei F, et al. SLC52A3 expression is activated by NF-κB p65/Rel-B and serves as a prognostic biomarker in esophageal cancer[J]. Cell Mol Life Sci, 2018, 75(14): 2643-2661. DOI:10.1007/s00018-018-2757-4.
[8]	姜洋, 金晓明, 屠康. 平均阳性染色面积百分比法分析免疫组化结果初探[J]. 生物医学工程学杂志, 2007, (03): 650-653. DOI:10.3969/j.issn.1671-4695.2018.03.015.Jiang Y, Jin XM, Tu K, et al. A primary study using the method of average positive stained area percentage to measure the immunohistochemistry results[J]. Journal of Biomedical Engineering, 2007, 24(3): 650-653. DOI:10.3321/j.issn:1001-5515.2007.03.039.
[9]	Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options[J]. J Clin Oncol, 2015, 33(23): 2563-2577. DOI:10.1200/JCO.2015.61.6706.
[10]	Wahdan-Alaswad RS, Edgerton SM, Salem HS, et al. Metformin targets glucose metabolism in triple negative breast cancer[J]. J Oncol Transl Res, 2018, 4(1) DOI:10.4172/2476-2261.1000129.
[11]	Li Z, Gong X, Zhang W, et al. Inhibition of miRNA-34a promotes triple negative cancer cell proliferation by promoting glucose uptake[J]. Exp Ther Med, 2019, 18(5): 3936-3942. DOI:10.3892/etm.2019.8017.
[12]	Ancey PB, Contat C, Meylan E. Glucose transporters in cancer—from tumor cells to the tumor microenvironment[J]. FEBS J, 2018, 285(16): 2926-2943. DOI:10.1111/febs.14577.
[13]	Kurahara H, Maemura K, Mataki Y, et al. Significance of glucose transporter type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma[J]. Ann Surg Oncol, 2018, 25(5): 1432-1439. DOI:10.1245/s10434-018-6357-1.
[14]	Schlüter A, Weller P, Kanaan O, et al. CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma[J]. BMC Cancer, 2018, 18(1): 272. DOI:10.1186/s12885-018-4180-5.
[15]	Katz H, Jafri H, Saad R, et al. Colonic obstruction from an unusual cause: a rare case of metastatic invasive ductal carcinoma to the colon[J]. Cureus, 2018, 10(5): e2588. DOI:10.7759/cureus.2588.
[16]	Wolff M, Kosyna FK, Dunst J, et al. Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells[J]. Arch Biochem Biophys, 2017, 613: 23-30. DOI:10.1016/j.abb.2016.11.002.
[17]	Halle MK, Ojesina AI, Engerud H, et al. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study[J]. Am J Obstet Gynecol, 2017, 217(4): 432.e1-432.e17. DOI:10.1016/j.ajog.2017.05.068.
[18]	王丽, 孙爱东, 袁昕, 等. 喉癌术后辅助放疗患者癌组织缺氧诱导因子-1α、葡萄糖转运蛋白-1表达及其与预后的相关性分析[J]. 临床和实验医学杂志, 2018, 17(03): 273-277. DOI:10.3969/j.issn.1671-4695.2018.03.015.Wang L,Sun AD,Yuan X,ea al.Expression of hypoxia inducible factor-1α and glucose transporter-1 in laryngeal carcinoma after adjuvant radiotherapy for larynge-al carcinoma and its correlation with prognosis[J]. Journal of Clinical and Experimental Medicine, 2018, 17(3): 273-277. DOI:10.3969/j.issn.1671-4695.2018.03.015.
[19]	Zhang B, Xie Z, Li B. The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: a meta-analysis[J]. Gene, 2019, 689: 76-83. DOI:10.1016/j.gene.2018.12.006.